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A B S T R A C T
The objective of this review is to give an overview of published cost of illness (COI) studies on status
epilepticus (SE).
For identifying COI studies that evaluated the direct and indirect costs of SE, a systematic literature
review was performed. We used a standardized assessment form for extracting information on the study
design, methodological framework, and data sources from each publication. The results were
systematically reported.
We identiﬁed only two studies worldwide, which included prevalence- or incidence-based data on
the direct costs of SE: one from Germany and one from the USA. Both used a bottom-up approach and a
prospective design. The estimated mean inpatient costs summed up to US$18,834 in the USA and to
s8347 in Germany per admission with an average length of stay of 12.9 and 14.0 days. The mean annual
direct costs for SE had been estimated at US$4 billion in the USA and at s83 million (adults only) in
Germany. Both available studies indicate that SE is a cost-intensive disorder with an acute CNS aetiology
as a cost-driving factor.
In conclusion, there is a paucity of data on the costs of SE. Further studies are warranted to determine
costs, its predictors, quality of life, mortality data due to SE and its sequelae and to provide a basis for
further cost-effectiveness calculations for new drugs and other interventions in SE and prolonged
seizures.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy, seizures and status epilepticus (SE) impose a
considerable burden on the affected person and society in general.1
SE itself is a life-threatening condition and a medical emergency
with different clinical deﬁnitions.2 Traditionally, SE was deﬁned as
a single clinical seizure lasting more than 30 min, or as repeated
seizures over a period of more than 30 min without intervening
recovery of consciousness.2,3 The operational deﬁnition was
recently modiﬁed for practical reasons of urgent treatment
initiation: persistent seizure activity for 5 min or more should
be therefore considered as SE and should be treated accordingly.2
Incidence is estimated at about 20/100,000 applying the traditional
deﬁnition and the mortality rate lies between 3 and 40%,
depending on factors like age and aetiology.3,4§ This review was presented in cooperation with the EpimiRNA-Consortium at
the 7th International Epilepsy Colloquium with Status Epilepticus Satellite in
Marburg, Germany on 29th May 2014.
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status epilepticus (SE) is associated with prolonged intensive care
treatment and high indirect costs because of its unfavourable
outcome with premature death or loss of productivity. Further-
more, it is unknown if the introduction of newer anti-epileptic
drugs causes an increase in direct costs or might be even cost-
effective in preventing prolonged hospital admissions.
Cost of illness (COI) studies estimate the costs which are
attributed to a particular disorder and therefore may provide
essential information on the burden of a disease to individuals and
society.1 The purpose of this article is to gather comprehensive
information on the currently available data on the costs incurred
due to SE.
2. Methods
2.1. Selection of studies
To identify studies that evaluated the costs of status epilepticus,
a systematic literature search in electronic databases was
performed, using a combined search strategy including the
following keywords: cost(s), status epilepticus, cost of illness,served.
Table 2
Potential direct cost-driving factors in detail.
Penberthy et al.
(2005), Seizure
Median
reimbursement
per admission
Strzelczyk et al.
(2013), Seizure
Mean costs
per admission
Age group Epilepsy diagnosis
0–16 US$6140 Status epilepticus s8347
17–45 US$14,689 Newly diagnosed
epilepsy
s1998
46–64 US$9520 Established
epilepsy
s3475
65+ US$8938
Race Race
Black US$8601 Black n.a.
White US$8039 White n.a.
Sex Sex
Male US$8135 Male n.a.
Female US$8234 Female n.a.
Aetiology Aetiology
Acute CNS injury US$16,919 Acute CNS injury s11,934
Hypoxia US$9738 Not acute
CNS injury
s4938
Not acute CNS injury US$6669
Remote/congenital US$7090
Withdrawal US$11,239
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MedLine, Cochrane’s database of systematic reviews and HTA
(Health Technology Assessment) of the UK NHS Centre for Reviews
and Dissemination. We examined the reference lists of all
identiﬁed studies for additional studies and asked clinical experts
for additional published studies.
It was assumed that this review should give a broad overview of
the COI of SE, all studies which analyzed direct and/or indirect
costs were considered, along with prevalence- and incidence-
based studies, as well as bottom-up, top-down and modelling
approaches to the COI.
2.2. Search results
A total of 65 abstracts were identiﬁed and reviewed in detail.
The majority was immediately discarded because of the lack of any
data on costs or the unavailable correlation between costs and
status epilepticus. Finally 14 studies were selected and were
retrieved in full text for subsequent revision. Only two studies
included prevalence- or incidence-based data on the costs of status
epilepticus and could be included in this review. These studies
evaluated the costs of epilepsy/status epilepticus in Germany5,6
and in the USA.7 Both studies used a bottom-up approach and
applied a prospective design.
3. Results
Table 1 shows the results of both included studies’ evaluating
costs of status epilepticus. Penberthy and colleagues reported on a
prospective cohort from the USA evaluated in 1993/1994 at one
centre in Virginia.7 Strzelczyk et al. described in detail a
population-based cohort of adult patients with SE evaluated
during a four-month period in 2008 in the German district of
Marburg-Biedenkopf5; the study details and analysis of epilepsy
patients had been previously published.6
3.1. Direct cost estimates
The study from the USA7 analyzed prospectively 192 patients in
all age groups and retrieved data on the direct costs for
reimbursement due to inpatient admissions. The estimated mean
direct costs summed up to US$18,834 per admission. The adult ageTable 1
Study details of COI studies.
Study
characteristics
Penberthy et al.
(2005), Seizure
Strzelczyk et al.
(2013),
Seizure
Country USA Germany
State/region Virginia Marburg-Biedenkopf
Year 1993/1994 (1 year) 2008 (4 months)
Design Prospective, all ages Prospective, adults
(>18 years)
Deﬁnition Single centre Population-based
Patients n = 192 (SE) n = 10 (SE); n = 96
(epilepsy)
SE deﬁnition 30 min 30 min
Aetiology Acute and remote
CNS injury,
hypoxic, withdrawal
(drugs, EtOH)
Acute and remote
CNS injury,
withdrawal
(AEDs only)
Direct hospital
cost/adm.
US$8417 (median) s4702 (median)
US$18,834 (mean) s8347 (mean)
Length of
hospital stay
n.a. (median) 10.5 days (median)
12.9 days (mean) 14.0  13.0 days (mean)
Cost-driving factors Acute CNS aetiology n.a.
Age (17–45 years,
46–64 years)group (17–45 years) were responsible for the highest amount, with
median costs of US$14,689, in contrast to the paediatric age group
(0–16 years), with median costs of US$6140 (Table 2). Further-
more, increased median costs were associated with admissions
due to an acute CNS aetiology (US$16,919 per adm.) in comparison
to non-acute CNS aetiology with US$6669 per admission. Gender
and race did not show any signiﬁcant differences concerning the
direct costs. The average length of stay for SE patients was 12.9
days, in comparison to other acute illness such as acute myocardial
infarction with a length of stay of 7.3 days (Table 3). The length of
stay varied markedly and over half the patients (104/192; 54%)
were admitted for less than one week. In this group the average
reimbursement was approximately US$7000. For patients with
over one-week’s stay the ﬁgure was US$32,907. Only 10% of
patients had an inpatient treatment over four weeks with resulting
costs of over US$60,000 per admission The authors’ projected
annual direct costs for the USA due to inpatient admissions for SE
were US$4 billion.
The German study5 used a population-based approach to
include prospectively all adult patients with epilepsy and SE from a
deﬁned district during a four-month period. The mean direct costs
per admission were calculated according to the German diagnosis-
related groups (G-DRG) and amounted to s8347. In comparison,
mean inpatient costs for newly diagnosed epilepsy were s1998
and s3475 for patients with established epilepsy (Table 2).
Inpatient treatment costs of SE due to an acute CNS aetiology wereTable 3
Mean length of stay due to SE in comparison to epilepsy and other medical
conditions.
Average length of stay in days
Penberthy
et al. (2005),
Seizure
Strzelczyk
et al. (2013),
Seizure
Status epilepticus 12.9 14
Newly diagnosed epilepsy n.a. 5.4
Established epilepsy n.a. 7.5
Acute myocardial infarction 7.3 n.a.
Congestive heart failure 7.5 n.a.
Intracranial haemorrhage 9.3 n.a.
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longer mean duration on admission (20.8 days) than patients with
a previous diagnosis of epilepsy (s4938; 7.2 days). Overall, this
study projected hospital costs of s83 million per year for adult
patients in Germany. These SE-associated costs constituted 24.4%
of the total inpatient costs for epileptic disorders, although the
patients represented only 10.4% of the study participants.
Table 3 presents the length of stay for different diagnoses.
Patients with SE were hospitalized for an average length of 12.9
days7 or 14 days,5 while other epileptic disorders and acute illness
have a signiﬁcantly shorter length of stay: for example, congestive
heart failure, with 7.3 days, or intracranial haemorrhage, with 9.3
days.
3.2. Indirect cost estimates
To date, no studies provide indirect costs attributed to acute
treatment of SE or to sequelae caused by SE.
4. Discussion
There is a vast paucity of health economic data describing the
costs associated with the acute treatment of SE or its long-term
sequelae. We identiﬁed only two studies on COI in SE and both
focused only on direct hospital admission costs due to SE.
Summarized, the direct costs for status epilepticus were higher
than those for established epilepsy or newly diagnosed epilepsy.5
In comparison to other acute health emergencies (myocardial
infarction, congestive heart failure, intracranial haemorrhage) the
reimbursement was 30–60% higher and underlines the high
economic burden.7 Cost-driving factors were an age group of
17–45 years and 46–64 years, as well as acute CNS aetiologies.
Even multivariate analysis demonstrated age and aetiology as
signiﬁcant independent predictors for higher direct costs.7
Calculating the annual direct costs associated with status
epilepticus, the extrapolation for Germany amounted to s83
million for adults5 and the extrapolation for the USA to US$4 billion
for all age groups.7 The huge difference in the extrapolation of costs
between the German (approx. 80 million inhabitants) and the US
(approx. 320 million inhabitants) studies can be explained by the
different epidemiological assumptions of SE incidence and
projection for adults only in the German study. The latter was
performed in a region with a low SE incidence – between 15.8 and
17.1 per 100,000 inhabitants4 with 11,000–12,000 affected adults
per year in Germany. The US study used epidemiological data from
DeLorenzo et al.8 with a high frequency of total SE episodes at 50
per year per 100,000 population. By that they assumed 200,000
episodes of SE per year in all age groups for their projection. Either
way, for the next decades the direct costs may even increase
because of the demographic change and therefore increasing
proportion of elderly patients.
Both studies show limitations inherent to COI analysis. Using
different methods of cost estimation it is difﬁcult to compare the
results. On the one hand the reimbursement used by Penberthy
et al. may not reﬂect the costs of providing care and support, and on
the other the DRG-system from the German study may not be
representative of other countries. Although both studies used the
traditional deﬁnition of SE (30 min),2,3 the large diversity of the
evaluation periods (1993/4 vs. 2008) and the number of
participants may have affect the results. Both studies used
different inclusion criteria: the US study7 also included patients
with hypoxia (anoxic and hypoxic insults) and alcohol withdrawal
in their SE cohorts, both groups were excluded in the German
study.5 Patients with post-anoxic coma have likely a prolonged
admission with high ICU costs and might be a confounder for cost
differences. Furthermore, it remains difﬁcult to draw the linebetween patients with post-anoxic SE and patients in coma with
electrographic seizure like changes.9,10 Regarding treatment of SE
only the German study provides details: seven out of ten patients
received pre-hospital benzodiazepines and the majority (6/10) was
treated with levetiracetam in hospital. During the evaluation
period of the US study levetiracetam was not yet on the market and
benzodiazepine use is not reported. The relatively short evaluation
period of four months in the German study, a small number of SE
patients (n = 10) and a restriction to one district (Marburg-
Biedenkopf) possibly led to a large variability of estimated costs
that may not be representative for the whole of Germany or for
other European countries.
A major problem with COI studies in SE is differentiating
between costs due to SE and costs associated with other acute
illness causing the SE (e.g. acute stroke underlying the SE).
The pre-hospital treatment may also be important, given that it
inﬂuences the cessation and therefore length of SE. Neither study
evaluated the inﬂuence of pre-hospital treatment on inpatient
costs and outcome. Established drugs for out-of-hospital treatment
are diazepam, lorazepam, clonazepam and midazolam as they can
be administered by laymen and paramedics using the buccal,
intranasal, intravenous and rectal route.11,12 A cost-effectiveness
study on oromucosal midazolam (Buccolam1) for the treatment of
prolonged acute convulsive seizures in children and adolescents
(<18 years) evaluated the use in the context of treatment
pathways in seven European countries.12,13 An efﬁcacy and
effectiveness advantage over rectal diazepam and other medica-
tions such as off-label buccal lorazepam or unlicensed buccal
midazolam was achieved. The calculations for ICU treatment costs
for prolonged seizures were based on estimations from a Delphi
panel or national price lists and varied hugely by a factor of 13.5
across the seven European countries – between s1115 and
s15,157 per admission (Scotland: s1574; Wales: s1574;
Germany: s1115; Spain: s2254; France: s8980; Italy: s4322;
Switzerland: s15,157). This evaluation of cost-effectiveness
demonstrates potential cost savings due to a pre-hospital
treatment of prolonged seizures, but also points towards the lack
of reliable data on inpatient costs for treatment of prolonged
seizures or SE.
5. Conclusion
Available COI studies conﬁrm SE as a cost-intensive disorder
and point towards an urgent need for more detailed and
comparable COI studies. Due to demographic change, the amount
of affected persons will rise and the budget impact for the
treatment of SE will increase. At the moment there is a complete
lack of studies on indirect costs or on cost due to sequelae caused
by SE. To date, no studies have used an operational deﬁnition of
persistent seizure activity for 5 min or more as signifying SE.
Further studies are warranted to determine costs, its predictors,
quality of life, mortality data due to SE and its sequelae and to
provide a basis for further cost-effectiveness calculations for new
drugs and other interventions in SE and prolonged seizures.
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